Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

AVMA Veterinary Practice Advertising Ethics

Veterinary advertising must not be false or misleading; only veterinarians certified by an AVMA-recognized specialty organization should be called specialists, and outcomes must not be guaranteed.

AVMA Principles of Veterinary Medical Ethics

British Columbia Professional Healthcare Advertising

BC physician and clinic ads must not guarantee outcomes, give success rates without a stated basis, or use testimonials as proof of efficacy.

CPSBC Practice Standard, Advertising and Communication with the Public (v8.1, June 29, 2026); Health Professions and Occupations Act, SBC 2022, c 43

CA Medical Advertising

California healing-arts ads must not be false or misleading, create unjustified expectations of results, use altered images, or misstate fees or board certification.

Cal. Bus. & Prof. Code §§ 651, 2271

CMS Skilled Nursing Facility Marketing

Nursing home and skilled nursing facility marketing must not state admission conditions federal law bans (waiving Medicare or Medicaid rights, private-pay promises, third-party guarantees) and must describe Medicare coverage and CMS star ratings accurately.

42 CFR 483.15(a)(2)-(3); 42 U.S.C. 1395i-3(c)(5)(A); 42 U.S.C. 1396r(c)(5)(A); 15 U.S.C. 45(a)(1)

CMS Stark Law Marketing Relationship Violations

Physician-owned hospitals must disclose physician ownership on their public websites and in public advertising, and marketing to physicians must not offer benefits tied to referrals for designated health services.

42 CFR 411.362(b)(3)(ii)(C); 42 U.S.C. 1395nn(a)(1); 42 U.S.C. 1320a-7b(b)(2)

CMS Telehealth Service Marketing

Telehealth marketing that mentions Medicare must state coverage accurately with eligibility and cost-sharing qualifications and must not use Medicare or HHS names in a way that implies government approval or affiliation.

42 U.S.C. 1320b-10(a)(1); 15 U.S.C. 45(a)(1); 42 CFR 410.78

Canada Health Product Advertising

In Canada, health product ads to the public may not claim to treat or cure Schedule A.1 diseases or exceed authorized claims, and prescription drug ads are limited to name, price and quantity.

Food and Drugs Act ss. 3, 9, Sch. A.1; FDR C.01.044

Canadian Medical Device Advertising

Canadian medical device ads must not make treatment or cure claims for Schedule A.1 diseases to the public, misrepresent Health Canada authorization, or make false or misleading claims.

Food and Drugs Act ss. 3, 20, Sch. A.1

Dutch Healthcare Advertising

Dutch healthcare provider ads must not guarantee outcomes, make unsupported superlative claims, or present individual results or prices misleadingly.

Burgerlijk Wetboek Boek 6 arts. 6:193c-6:193e; Nederlandse Reclame Code arts. 7-8 (8.2, 8.4)

EC Unfair Healthcare Commercial Practices

EU health marketing must not falsely claim to cure illness, guarantee outcomes, misuse professional endorsements, or exploit fear or vulnerability.

Directive 2005/29/EC Arts 6, 8-9, Annex I point 17

EMTALA (Emergency Medical Treatment and Labor Act) Marketing Compliance

Emergency department marketing by Medicare-participating hospitals must not state or imply that insurance, payment or network status is required before emergency screening or stabilization, or steer patients away by coverage.

42 U.S.C. 1395dd(a)-(c), (h); 42 CFR 489.24(a), (d)(4), (e)

EU Cross-Border Healthcare Advertising

Healthcare ads across the EU may not mislead about practitioners' qualifications, titles or licensing, such as implying an EU-wide licence.

Directive 2005/29/EC Art 6(1)(f); Directive 2005/36/EC Arts 4, 52

EU Digital Healthcare Platform Advertising

In the EU, influencer and creator content promoting healthcare services must clearly disclose that it is paid or incentivised promotion.

Directive 2005/29/EC Art 7(2), Annex I points 11, 22; Regulation (EU) 2022/2065 Art 26(2)

EU Digital Services Act - Healthcare Platform Advertising

In the EU, paid advertorials, native ads and sponsored rankings for healthcare providers must be clearly labelled as advertising and name the advertiser.

Directive 2005/29/EC Art 7(2), (4a), Annex I points 4, 11, 11a; Regulation (EU) 2022/2065 Arts 25, 26

EU E-commerce Directive - Online Healthcare Marketing

EU online healthcare providers must make their identity and regulatory details easily accessible on their site or app, and commercial emails must identify the sender and offer conditions.

Directive 2000/31/EC Arts 5(1), 6

EU Electronic Healthcare Marketing Privacy Violations

EU healthcare electronic marketing needs prior consent or a valid soft opt-in, must identify the sender and must offer a free opt-out in every message.

Directive 2002/58/EC Art 13; Regulation (EU) 2016/679 Arts 4(11), 7(2), (4)

EU Medical Device Marketing

MDR Art. 7 bars device advertising that misleads about intended purpose, safety or performance, for example by ascribing functions the device lacks or suggesting uses outside its intended purpose.

Regulation (EU) 2017/745 Art 7(a)-(d); Regulation (EU) 2017/746 Art 7

EU Medical Device Regulation Marketing Requirements

Medical device labels and packaging placed on the EU market must carry CE marking (with notified body number where applicable), device and manufacturer identification, the medical-device indication and UDI under the MDR.

Regulation (EU) 2017/745 Arts 7, 20, Annex I section 23.2

FCC Healthcare Telephone/Text Marketing

Healthcare calls and texts keep their TCPA healthcare exemption only if they contain no marketing and meet content limits; marketing messages need an opt-out method and prerecorded calls need caller ID and an automated opt-out.

47 U.S.C. 227; 47 CFR 64.1200(a)(3)(v), (a)(9)(iv), (a)(10), (b); 91 FR 67214

FDA False or Misleading Medical Device Claims

Device promotion must not make false, absolute or unsubstantiated performance, safety or superiority claims; quantified and comparative claims need a cited basis.

21 U.S.C. 352(a)(1), 352(q)(1); 15 U.S.C. 45, 52; FTC Advertising Substantiation Policy Statement

FDA Medical Device Advertising and Promotion

Device promotion must describe FDA status accurately (cleared, approved or De Novo authorized), must not imply approval from registration, must not promote investigational devices, and restricted-device ads need a brief risk statement.

21 U.S.C. 352(a), (q), (r); 21 CFR 807.39, 807.97, 812.7

FDA Non-Compliant Medical Software Marketing

Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.

21 U.S.C. 321(h), 352(a), 360j(o)(1)

FDA Off-Label Promotion of GLP-1 Weight Loss (Ozempic, Wegovy)

GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.

21 U.S.C. 352(a), (n), (bb), 353a, 353b; 21 CFR 202.1(e)

FDA SaMD Marketing

SaMD marketing must use the correct FDA status term (approved only for PMA devices, cleared for 510(k)), must not imply FDA endorsement or treat registration as approval, and must not claim uses beyond the authorized intended use.

21 U.S.C. 352(a), (o); 21 CFR 801.4, 807.39, 807.97

FDA Sexual Wellness Medical Device Requirements

Sexual wellness products that make therapeutic, contraceptive or STI-prevention claims are regulated as medical devices and may make those claims only within an FDA clearance or approval.

21 U.S.C. 321(h)(1), 352(a)(1), 352(o); 21 CFR 807.39, 807.97, 884.5300

FDA Telehealth & Online Pharmacy Advertising

Telehealth and online pharmacy ads must not claim or imply that compounded drugs are FDA-approved, generic or equivalent to branded drugs, or proven safe and effective, and ads making drug benefit claims must include risk information.

21 U.S.C. 352(a), (n), (bb), 353(b)(1); 21 CFR 202.1; 15 U.S.C. 45, 52

FDA Unauthorized Medical Device Off-Label Promotion

Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.

21 U.S.C. 352(a), (o), (q), (r); 21 CFR 801.4

FL Healthcare Professional Advertising

Florida physician and practitioner ads must not be false, deceptive or misleading, including unsupported success rates, guarantees and specialty claims.

Fla. Stat. 456.072(1)(a), 458.331(1)(d), 458.3312; Fla. Admin. Code 64B8-11.001

FTC Medical Device - Consumer Device Advertising Standards

Consumer medical device ads must be truthful and substantiated, must state FDA status accurately ('cleared' vs 'approved'; registration is not approval), and must disclose limitations where omission would mislead.

15 U.S.C. 45, 52, 55; 21 CFR 807.39; 16 CFR 255.2(b); FTC Health Products Compliance Guidance §§ III.A.2, III.B.2, III.C.4

False Healthcare Claims for Federal Programs

Healthcare marketing must not promote items or services as free because Medicare or Medicaid will be billed regardless of need, or suggest billing federal programs for services not needed, not ordered or not provided.

31 U.S.C. 3729-3733; 42 U.S.C. 1320a-7a(a)(1); 42 U.S.C. 1320a-7b(b), (g)

Federal No Surprises Act — Pharmacy and Healthcare Service Pricing

Healthcare providers and facilities must post the No Surprises Act balance-billing protections disclosure and the right-to-Good-Faith-Estimate notice on their websites, and patient communications must not contradict those protections.

42 U.S.C. 300gg-131 to 300gg-136; 45 CFR 149.410, 149.420, 149.430, 149.610

GMC Medical Practitioner Advertising

UK doctors must keep information about their services factual and verifiable, avoid guarantees and pressure offers, and give balanced risk information.

GMC Good Medical Practice (2024) paras 89(a)-(d), 90(c); GMC Guidance for doctors who offer cosmetic interventions, 'Maintaining trust' (marketing)

German Medical Device Marketing

German medical device ads must not mislead about efficacy or certification, promise success, or use misleading testimonials.

Heilmittelwerbegesetz (HWG) §§ 3, 11(1) Satz 1 Nr. 11 and Satz 2; Regulation (EU) 2017/745 (MDR) Art. 7

HIPAA Marketing Amendments

Covered entities need a patient's written HIPAA authorization before using health information for marketing, including third-party-sponsored messages to patients about their conditions.

45 CFR 164.501, 164.502(a)(5)(ii), 164.508(a)(3)-(4)

HIPAA Unauthorized PHI Marketing Use

Covered entities may not disclose patient information to advertising platforms through trackers on authenticated pages, patient-list uploads, or retargeting without HIPAA authorization.

45 CFR 164.502(a), 164.508(a)(3)

Health Canada Digital Therapeutics Advertising

Digital therapeutics and SaMD advertised in Canada may not be promoted to the public as treating, preventing or curing Schedule A.1 diseases, must not be advertised in a false or misleading way, and Class II-IV devices may not be advertised for sale before they are licensed.

Food and Drugs Act ss. 3, 20, Sch. A.1; Medical Devices Regulations s. 27

Health Canada Medical Device Advertising

Canadian medical device ads must stay within the licensed indication, not be misleading, and not promote treatment, prevention or cure of Schedule A.1 diseases to the public.

Food and Drugs Act ss. 3, 20, Sch. A.1; MDR s. 27

Healthcare Professional Advertising

Alberta regulated health professionals must not advertise falsely or in ways that exploit patient fear or vulnerability.

Health Professions Act, RSA 2000, c H-7, s. 102

IL Misleading Healthcare Testimonials

Illinois physician advertising must not be false or misleading, so patient testimonials and before-and-after images may not misrepresent typical results or hide paid relationships.

225 ILCS 60/26; 225 ILCS 60/22(A)

KY Prohibited Patient Testimonials

Kentucky physician ads may use testimonials only if they are not false, deceptive or misleading, for example by presenting atypical results as typical or hiding paid endorsements.

KRS 311.595(9); KRS 311.597(2)(a)-(b)

Manitoba Healthcare Professional Advertising

Manitoba regulated health professionals' ads must present titles, credentials and specialties accurately and avoid guarantees and unverifiable superlatives.

The Regulated Health Professions Act, C.C.S.M. c. R117; CPSM Standard of Practice: Advertising s. 1.2

Michigan Healthcare Advertising

Michigan health professional advertising must not be false or misleading about credentials, certifications, specialties, outcomes or affiliations.

MCL 333.16221(d)(i), (e)(i)

NC Healthcare Provider Advertising

North Carolina physician ads must not be false, deceptive or unsubstantiated, including guarantees, unsupported success rates and inaccurate board-certification claims.

N.C. Gen. Stat. § 90-14(a)(6), (a)(8); North Carolina Medical Board Position Statement 8.3.1, Advertising and Publicity (adopted Nov. 1999, amended Jul. 2026) (guidance)

OH Healthcare Professional Advertising

Ohio physician ads must not contain false, fraudulent, deceptive or misleading statements, including unjustified expectations of results and unsupported outcome claims.

R.C. 4731.22(B)(5)

OIG Healthcare Kickback Violations

Prohibits marketing that offers payment or anything of value for referrals or for ordering services and products paid for by Medicare, Medicaid or other federal health programs.

42 U.S.C. 1320a-7b(b); 42 U.S.C. 1320a-7a(a)(5); 42 CFR 1001.952

OIG Patient Inducement Marketing Violations

Bars advertising routine waivers of Medicare or Medicaid copays, coinsurance or deductibles; waivers are allowed only case by case for financial need and never advertised.

42 U.S.C. 1320a-7a(a)(5), (i)(6)(A); 42 CFR 1003.110

Ontario Health Data in Marketing

Ontario health information custodians need express consent to use personal health information for marketing or market research; fundraising may rely on implied consent using only name and contact details, must offer an easy opt-out and must not reveal the patient's health information.

PHIPA, S.O. 2004, c. 3, Sched. A, ss. 18, 32-33; O. Reg. 329/04 s. 10

Ontario Non-Compliant Healthcare Professional Advertising

Ontario regulated health professionals must keep ads truthful and verifiable, avoiding unsupported success rates, superiority claims and prohibited testimonials.

Regulated Health Professions Act, 1991, Sched. 2 (Health Professions Procedural Code) s. 95(1)(l); CPSO Advertising Policy; O. Reg. 114/94

PA Medical Advertising

Pennsylvania physician and clinic ads must not make false, deceptive or misleading claims about outcomes, safety, credentials or superiority.

49 Pa. Code § 16.61(a)(4)-(5); 63 P.S. § 422.41(2), (8)

Quebec Healthcare Professional Advertising

Quebec health professionals must not guarantee results or make unsupported outcome claims, must give risk information, and must advertise in French.

Professional Code, CQLR c. C-26; Code of ethics of physicians, CQLR c. M-9, r. 17, ss. 88-92; Charter of the French Language, CQLR c. C-11, s. 58

TX Healthcare Advertising

Texas physician ads must not be false, misleading or deceptive about outcomes, credentials or specialties, and board-certification claims must meet 22 TAC 164.4.

22 Tex. Admin. Code §§ 164.3(b), 164.4(a); Tex. Occ. Code § 101.201

Telehealth Marketing

Telehealth ads must not overstate what virtual care can do, guarantee prescriptions or outcomes, or imply Medicare or government endorsement.

15 U.S.C. 45(a)(1), 52(a); 42 U.S.C. 1320b-10(a)(1)

U.K. Medical Device Advertising

UK medical device ads must not misstate the device's regulatory status (for example 'MHRA approved'), promote uses outside its intended purpose, guarantee results or make unsupported efficacy claims.

CAP Code s 3, s 12; DMCC Act 2024 Part 4; UK MDR 2002

UK MHRA AI as Software as Medical Device (SaMD)

UK marketing of software or AI tools with medical-purpose claims must be consistent with their medical-device status, must not claim MHRA approval and must substantiate performance claims.

UK MDR 2002 (SI 2002/618) reg. 2; MHRA 'Register medical devices to place on the market'; CAP Code rules 3.7, 12.1

UK MHRA Medical Device Advertising

UK medical device ads must stay within the intended purpose and avoid unsubstantiated, comparative or cure claims.

CAP Code rules 3.7, 3.33-3.34, 3.37, 12.1, 12.2, 12.7, 12.9

UT Mental Health Chatbot Advertising and AI Disclosure (HB 452)

Suppliers of mental health chatbots used by Utah users must clearly disclose that the chatbot is AI and not human, must label any in-conversation ad and disclose sponsorships, and may not use what users type to target or tailor ads.

Utah Code §§ 13-72a-201 to -203

Unauthorized Health Information Marketing Use

Covered entities may not use identifiable patient information, including names, faces, conditions or review details, in marketing or social content without the patient's HIPAA authorization.

45 CFR 164.501, 164.502(a), 164.508(a)(3), 164.514(b)

Unauthorized NHS Branding Use

Advertisers must not use the NHS logo or imply NHS approval, endorsement or partnership unless they are an NHS organisation or an authorised provider describing NHS services.

NHS Identity Guidelines; TMA 1994 s 10; DMCC Act 2024 Sch 20; CAP s 3

Unauthorized Personal Information Use in Marketing

Canadian health care providers need the patient's express consent before using identifiable health information, stories or images in marketing.

PIPEDA Sch. 1 cl. 4.2, 4.3; s. 6.1; PHIPA 2004 (ON) s. 33

WV Prohibited Patient Testimonials

West Virginia physician ads may use testimonials only if they are not false, deceptive or misleading, for example by implying atypical results are typical or hiding paid endorsements.

W. Va. Code § 30-3-14(c)(3); W. Va. Code § 30-3-14(c)(9); W. Va. Code R. § 11-1A-12.1.hh; W. Va. Code R. § 11-1A-12.1.ii.B; W. Va. Code R. § 11-1A-12.1.ii.C; W. Va. Code R. § 11-1A-12.2.b

Browse by category

Browse by jurisdiction

Browse by regulator